Teladoc Health stock may be undervalued by about 40% based on a discounted cash flow model, which estimates an intrinsic value of roughly $15.08 per share. The company generated about $148.1 million in free cash flow over the last twelve months, and the model projects growing cash flows over time. On a price-to-sales basis, Teladoc trades at about 0.7 times, well below the healthcare services industry average of roughly 2.6 times and a modeled fair ratio of about 2.0 times. Expanded insurance coverage, a Walmart partnership, and AI initiatives support growth expectations, though a history of net losses remains a key risk. Community narratives show a bull case of 14% undervaluation and a bear case of 23% overvaluation, hinging on the shift toward lower-margin insurance revenue.
Teladoc IncAnalyst DCF model suggests 40% undervaluation, with intrinsic value $15.08 vs current price.
Walmart Inc.